Large gap with delayed quotes
|
Last quote
11/04/2025
-
02:00:00
|
Bid
11/04/2025 -
13:24:48
|
Bid Volume |
Ask
11/04/2025 -
13:24:48
|
Ask Volume |
|---|---|---|---|---|
|
10.20
+0.10
(
+0.99% )
|
9.77
|
100 |
10.05
|
100 |
Analysis date: 31.10.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 15.07.2025.
Interest
Weak
Weak
Two stars since 31.10.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 02.09.2025 at a price of 58.56.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 30.09.2025.
4wk Rel Perf
38.60%
38.60%
The four-week dividend-adjusted overperformance versus SP500 is 38.60%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.07%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 7.07%.
Mkt Cap in $bn
0.65
0.65
With a market capitalization <$2bn, MOONLAKE IMMUNOTHERAPEUTICS is considered a small-cap stock.
G/PE Ratio
-1.88
-1.88
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-2.80
-2.80
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-5.27%
-5.27%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
30
30
For 1% of index variation, the stock varies on average by 0.30%.
Correlation
0.06
0.06
Stock movements are totally independent of index variations.
Value at Risk
9.59
9.59
The value at risk is estimated at USD 9.59. The risk is therefore 95.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025